<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30356372</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">2314-6141</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>2018</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>BioMed research international</Title>                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>            </Journal>            <ArticleTitle>Efficient Synthesis of Glutamate Peptide-Estradiol Conjugate for Imaging Estrogen Receptor-Positive Diseases.</ArticleTitle>            <Pagination>                <MedlinePgn>5208964</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2018/5208964</ELocationID>            <Abstract>                <AbstractText>Molecular imaging of estrogen receptor-positive (ER+) pathway-activated system serves the basis of ER+ disease management such as cancers and endometriosis. ER+ patients have better response to endocrine therapy and survive twice as long as negative ER patients. However, tumor resistance resulting from clinical used aromatase inhibitors and antiestrogens is unpredictable. Radiolabeled ER+ ligand could quantify ER+ tissue uptake which helps to stage and restage of the cancer as well as endometriosis. The differential diagnosis of ER+ lesions by using a labeled ligand helps to select the patients for optimal response to endocrine therapy and to discontinue the treatment when resistance occurs. In addition, radiolabeled ER+ ligand serves as basis for image-guided response follow-up. Glutamate receptors are cell surface receptors which are overexpressed in inflammation and infection. Using glutamate peptide as a drug carrier helps to target intracellular genes via glutamate receptor-mediated process. Reports have shown that polyglutamate is a drug carrier that could alter drug solubility and enhance estrogen receptor-ligand binding pocket. However, polyglutamate was a blend of mixed polymer with a wide range of molecular weight. Thus, the structural confirmation and purity of the conjugates were not optimized. To overcome this problem, the efficient synthesis of glutamate peptide-estradiol (GAP-EDL) conjugate was achieved with high purity. EDL was conjugated site-specific at the first glutamate of GAP. The average cell uptake of <sup>68</sup>Ga-GAP-EDL was 5-fold higher than the previous reported synthesis. The efficient synthesis of GAP-EDL has greatly enhanced sensitivity and specificity in cell uptake studies. In vivo PET imaging studies indicated that <sup>68</sup>Ga-GAP-EDL could image ER (+) tumors in MCF-7 tumor-bearing mice. Therefore, GAP-EDL makes it possible to image ER-enriched endometriosis and cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Shih</LastName>                    <ForeName>Ming-Chi</ForeName>                    <Initials>MC</Initials>                    <Identifier Source="ORCID">0000-0003-0642-3664</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, School of Medicine, Federal University of Rio De Janeiro, Rio De Janeiro, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Simon</LastName>                    <ForeName>Sergio Daniel</ForeName>                    <Initials>SD</Initials>                    <AffiliationInfo>                        <Affiliation>Brazilian Breast Cancer Study Group (GBECAM), Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jin</LastName>                    <ForeName>Zhiming</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Jiangsu Huayi Technology Co., Ltd, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gui</LastName>                    <ForeName>Yuan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Jiangsu Huayi Technology Co., Ltd, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Bohua</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Jiangsu Huayi Technology Co., Ltd, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Zhihong</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Jiangsu Huayi Technology Co., Ltd, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rosado-de-Castro</LastName>                    <ForeName>Paulo Henrique</ForeName>                    <Initials>PH</Initials>                    <Identifier Source="ORCID">0000-0003-0091-9714</Identifier>                    <AffiliationInfo>                        <Affiliation>Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Silveira Braghirolli</LastName>                    <ForeName>Ana Maria</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Nuclear Engineering Institute, National Nuclear Energy Commission, Rio de Janeiro, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Barbosa da Fonseca</LastName>                    <ForeName>Lea Mirian</ForeName>                    <Initials>LM</Initials>                    <Identifier Source="ORCID">0000-0002-4660-7196</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Inoue</LastName>                    <ForeName>Tomio</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Director of Advanced Medical Center, Shonan Kamakura General Hospital, Kamakura, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>David J</ForeName>                    <Initials>DJ</Initials>                    <Identifier Source="ORCID">0000-0001-8308-0621</Identifier>                    <AffiliationInfo>                        <Affiliation>Vyripharm Biopharmaceuticals LLC, Houston, Texas, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Biomed Res Int</MedlineTA>            <NlmUniqueID>101600173</NlmUniqueID>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Steroid Biochem Mol Biol. 2016 Jul;161:84-91</RefSource>                <PMID Version="1">26873133</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acad Radiol. 2007 Sep;14(9):1050-7</RefSource>                <PMID Version="1">17707312</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Comp Biochem Physiol B. 1992 May;102(1):159-62</RefSource>                <PMID Version="1">1382005</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Nucl Med Mol Imaging. 2007 Mar;34(3):354-62</RefSource>                <PMID Version="1">17021817</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nucleic Acids Symp Ser. 1985;(16):121-4</RefSource>                <PMID Version="1">2418418</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr Relat Cancer. 2003 Jun;10(2):193-202</RefSource>                <PMID Version="1">12790782</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Nanomedicine. 2017 Jan 13;12:577-591</RefSource>                <PMID Version="1">28144140</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1984 Jan;44(1):25-30</RefSource>                <PMID Version="1">6197162</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2012 Aug 31;14(4):212</RefSource>                <PMID Version="1">22963717</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pharmacobiodyn. 1984 Sep;7(9):688-98</RefSource>                <PMID Version="1">6084708</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bone. 1998 Apr;22(4):295-9</RefSource>                <PMID Version="1">9556127</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2004 Mar;5(3):174-81</RefSource>                <PMID Version="1">15003201</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Mol Neurobiol. 2018 Mar;38(2):497-505</RefSource>                <PMID Version="1">28477054</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Redox Biol. 2015 Aug;5:33-42</RefSource>                <PMID Version="1">25827424</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Chemosphere. 2017 Oct;184:679-686</RefSource>                <PMID Version="1">28628905</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Soc Exp Biol Med. 1959 Apr;100(4):778-80</RefSource>                <PMID Version="1">13645717</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Drug Deliv Rev. 2002 Sep 13;54(5):695-713</RefSource>                <PMID Version="1">12204599</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30356372</ArticleId>            <ArticleId IdType="doi">10.1155/2018/5208964</ArticleId>            <ArticleId IdType="pmc">PMC6176321</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>